A Pilot Study of Acalabrutinib With Bendamustine/Rituximab Followed by Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
TRIAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
    Bega, Giulia
    Olivieri, Jacopo
    Riva, Marcello
    Scapinello, Greta
    Paolini, Rossella
    Finotto, Silvia
    Sartori, Roberto
    Lucchini, Elisa
    Guandalini, Gianmarco
    Facchinelli, Davide
    Tisi, Maria Chiara
    Basso, Marco
    Ballotta, Laura
    Piazza, Francesco
    Ferrarini, Isacco
    Visco, Carlo
    CANCERS, 2021, 13 (23)
  • [2] Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study
    Shimizu, Yuki
    Kaji, Daisuke
    Watanabe, Otoya
    Yamaguchi, Kyosuke
    Kageyama, Kosei
    Taya, Yuki
    Nishida, Aya
    Ishiwata, Kazuya
    Takagi, Shinsuke
    Yamamoto, Hisashi
    Mori, Yuki-Asano
    Wake, Atsushi
    Uchida, Naoyuki
    Taniguchi, Shuichi
    Yamamoto, Go
    CANCER MEDICINE, 2023, 12 (11): : 12548 - 12552
  • [3] Bendamustine-rituximab in mantle cell lymphoma
    Lipsky, Andrew
    Martin, Peter
    LANCET HAEMATOLOGY, 2017, 4 (01): : E2 - E3
  • [4] Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
    Villa, Diego
    Hoster, Eva
    Hermine, Olivier
    Klapper, Wolfram
    Szymczyk, Michal
    Bosly, Andre
    Unterhalt, Michael
    Rimsza, Lisa M.
    Ramsower, Colleen A.
    Freeman, Ciara L.
    Scott, David W.
    Gerrie, Alina S.
    Savage, Kerry J.
    Sehn, Laurie H.
    Dreyling, Martin
    BLOOD ADVANCES, 2022, 6 (18) : 5285 - 5294
  • [5] Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis
    Yi, Jun Ho
    Kim, Seok Jin
    Lee, Jeong-ok
    Lee, Gyeong-won
    Kwak, Jae-yong
    Eom, Hyeon-seok
    Jo, Jae-cheol
    Choi, Yoon Seok
    Oh, Sung Yong
    Kim, Won Seog
    ANTICANCER RESEARCH, 2022, 42 (12) : 6083 - 6089
  • [6] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [7] Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters
    Falchi, Lorenzo
    Morales, Rita
    Ruella, Marco
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S590 - S594
  • [8] Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma
    Villa, Diego
    Sehn, Laurie H.
    Savage, Kerry J.
    Toze, Cynthia L.
    Song, Kevin
    den Brok, Wendie D.
    Freeman, Ciara L.
    Scott, David W.
    Gerrie, Alina S.
    BLOOD ADVANCES, 2020, 4 (15) : 3486 - 3494
  • [9] Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients
    Morigi, Alice
    Argnani, Lisa
    Lolli, Ginevra
    Broccoli, Alessandro
    Pellegrini, Cinzia
    Nanni, Laura
    Stefoni, Vittorio
    Coppola, Paolo Elia
    Carella, Matteo
    Casadei, Beatrice
    Sabattini, Elena
    Cavo, Michele
    Zinzani, Pier Luigi
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (04) : 487 - 492
  • [10] Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
    Burke, John M.
    van der Jagt, Richard H. C.
    Kahl, Brad S.
    Wood, Peter
    Hawkins, Tim E.
    MacDonald, David
    Hertzberg, Mark
    Simpson, David
    Craig, Michael
    Kolibaba, Kathryn
    Issa, Samar
    Munteanu, Mihaela
    Victor, Timothy W.
    Flinn, Ian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (04) : 182 - +
12345